OA10226A - Method of reversing resistance of hiv-1 strains to zidovudine - Google Patents
Method of reversing resistance of hiv-1 strains to zidovudine Download PDFInfo
- Publication number
- OA10226A OA10226A OA60701A OA60701A OA10226A OA 10226 A OA10226 A OA 10226A OA 60701 A OA60701 A OA 60701A OA 60701 A OA60701 A OA 60701A OA 10226 A OA10226 A OA 10226A
- Authority
- OA
- OAPI
- Prior art keywords
- zidovudine
- amino
- strains
- dichlorobenzeneacetamide
- hiv
- Prior art date
Links
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title claims abstract description 40
- 229960002555 zidovudine Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 7
- -1 2-nitrophenyl Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 2
- 229950006243 loviride Drugs 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 16
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 abstract description 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 5
- 229960002656 didanosine Drugs 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- NAFOOGOADMAIJN-UHFFFAOYSA-N 2-anilino-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NC1=CC=CC=C1 NAFOOGOADMAIJN-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 101710145242 Minor capsid protein P3-RTD Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Testing Or Measuring Of Semiconductors Or The Like (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Adornments (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2128693A | 1993-02-22 | 1993-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10226A true OA10226A (en) | 1997-10-07 |
Family
ID=21803366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA60701A OA10226A (en) | 1993-02-22 | 1995-08-22 | Method of reversing resistance of hiv-1 strains to zidovudine |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0684818B1 (de) |
| JP (1) | JP2669937B2 (de) |
| CN (1) | CN1118137A (de) |
| AT (1) | ATE179601T1 (de) |
| AU (1) | AU676021B2 (de) |
| CA (1) | CA2155829A1 (de) |
| DE (1) | DE69418312D1 (de) |
| OA (1) | OA10226A (de) |
| SG (1) | SG49651A1 (de) |
| WO (1) | WO1994018963A1 (de) |
| ZA (1) | ZA941178B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0872233A1 (de) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretrovirale Arzneimittel mit verbesserter Bioverfügbarkeit |
| TR200200763T2 (tr) | 1999-09-24 | 2003-09-22 | Janssen Pharmaceutica N.V. | Antiviral bileşimler |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68900926D1 (de) * | 1988-09-28 | 1992-04-09 | Sigma Tau Ind Farmaceuti | Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen. |
| IE75693B1 (en) * | 1990-07-10 | 1997-09-10 | Janssen Pharmaceutica Nv | HIV-inhibiting benzeneacetamide derivatives |
| IL99843A0 (en) * | 1990-11-01 | 1992-08-18 | Merck & Co Inc | Synergistic combination of hiv reverse transcriptase inhibitors |
-
1994
- 1994-02-10 SG SG1996002809A patent/SG49651A1/en unknown
- 1994-02-10 EP EP94908308A patent/EP0684818B1/de not_active Expired - Lifetime
- 1994-02-10 CA CA002155829A patent/CA2155829A1/en not_active Abandoned
- 1994-02-10 AT AT94908308T patent/ATE179601T1/de not_active IP Right Cessation
- 1994-02-10 JP JP6518629A patent/JP2669937B2/ja not_active Expired - Lifetime
- 1994-02-10 AU AU61398/94A patent/AU676021B2/en not_active Ceased
- 1994-02-10 CN CN94191262A patent/CN1118137A/zh active Pending
- 1994-02-10 DE DE69418312T patent/DE69418312D1/de not_active Expired - Lifetime
- 1994-02-10 WO PCT/EP1994/000428 patent/WO1994018963A1/en not_active Ceased
- 1994-02-21 ZA ZA941178A patent/ZA941178B/xx unknown
-
1995
- 1995-08-22 OA OA60701A patent/OA10226A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0684818A1 (de) | 1995-12-06 |
| ZA941178B (en) | 1995-08-21 |
| WO1994018963A1 (en) | 1994-09-01 |
| DE69418312D1 (de) | 1999-06-10 |
| JPH08505642A (ja) | 1996-06-18 |
| CN1118137A (zh) | 1996-03-06 |
| AU676021B2 (en) | 1997-02-27 |
| EP0684818B1 (de) | 1999-05-06 |
| AU6139894A (en) | 1994-09-14 |
| SG49651A1 (en) | 1998-06-15 |
| JP2669937B2 (ja) | 1997-10-29 |
| ATE179601T1 (de) | 1999-05-15 |
| CA2155829A1 (en) | 1994-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robins et al. | HIV protease inhibitors: their anti-HIV activity and potential role in treatment | |
| Merluzzi et al. | Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor | |
| Poppe et al. | Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor | |
| Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
| EP0876387B1 (de) | Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren | |
| Buckheit Jr et al. | Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor | |
| EP0735890B1 (de) | Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten | |
| DK3127542T3 (en) | ANTIVIRAL THERAPY | |
| ES2250363T3 (es) | Guanilhidrazonas aromaticas farmaceuticamente activas. | |
| Pereira et al. | Anti-HIV drug development-an overview | |
| WO2008097654A1 (en) | Methods of using saha for treating hiv infection | |
| Malet et al. | The future of integrase inhibitors of HIV-1 | |
| Liu et al. | Viral manipulations of the cullin-RING ubiquitin ligases | |
| OA10226A (en) | Method of reversing resistance of hiv-1 strains to zidovudine | |
| Mo et al. | Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir | |
| PT605700E (pt) | Composicao farmacutica a base de flavopereirina e sua utilizacao no tratamento contra o virus hiv | |
| Tobin et al. | Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay | |
| Mahmood et al. | Medicinal Chemistry: Anti‐HIV Activity and Mechanism of Action of Macrocyclic Diamide SRR‐SB3 | |
| JPH0262533B2 (de) | ||
| WO1996041634A2 (en) | Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection | |
| MO et al. | Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease | |
| WO2025183089A1 (ja) | 潜伏感染しているｈｉｖを再活性化するための組成物 | |
| EP1452605A1 (de) | Verfahren zum Nachweis von antiviraler Aktivität | |
| Terrazas-Aranda et al. | HIV-1 Integration: A Potential Target for Microbicides to Prevent Cell-free or Cell-1 associated Human Immunodeficiency Virus type-1 Infection 2 | |
| Pereira et al. | APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro |